KR101879596B1 - Composition for preventing, improving or treating respiratory inflammatory disease comprising Chamaecyparis obtusa essential oil as effective component - Google Patents

Abstract

The present invention relates to a composition for preventing, improving or treating respiratory inflammatory diseases comprising Chamaecyparis obtusa essential oil as an effective component, wherein the Chamaecyparis obtusa essential oil of the present invention has an excellent effect of inhibiting an inflammatory response reaction of peripheral blood monocytes and respiratory epithelial cells, and has an excellent therapeutic effect in an allergic rhinitis model, thereby being usefully used as a health functional food composition and a pharmaceutical composition for preventing, improving or treating the respiratory inflammatory diseases.

Description

[0001] The present invention relates to a composition for preventing, ameliorating or treating respiratory inflammatory diseases,

The present invention relates to a composition for preventing, ameliorating or treating a respiratory inflammatory disease containing an essential oil of whey protein as an active ingredient.

Respiratory diseases are usually accompanied by inflammation, which can exacerbate the condition of the bronchi and lungs. In this regard, respiratory inflammatory diseases include bronchitis, allergic rhinitis, otitis media, sore throat, tonsillitis, pneumonia, asthma and chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is a group of pulmonary diseases characterized by irreversible airflow limitation, which is caused by chronic airway inflammation and pulmonary parenchymal damage. Chronic obstructive pulmonary disease is caused by the interaction of external factors such as smoking, indoor and outdoor air pollution, socioeconomic status, respiratory infections, and host factors such as gene, age, sex, airway hyperresponsiveness, and lung growth and is associated with cardiovascular disease, diabetes, , Osteoporosis, depression, and lung cancer.

Asthma is a chronic allergic inflammatory disease of the airways, airway inflammation is a cause of airway hyperresponsiveness, and it causes symptoms such as repetitive wheezing, dyspnea, chest tightness, and coughing. Asthma is a genetic disorder that is caused by a combination of genetic and environmental factors, and it tends to occur in families. Atopy is a very important factor in the development of asthma.

Both chronic obstructive pulmonary disease and asthma cause an inflammatory response in the respiratory tract, but the associated inflammatory phenomena, inflammatory cells and inflammatory mediators are different. For example, in terms of inflammation, asthma acts on the entire airway and causes airway hyper-reactivity (AHR), epithelial cell shedding, fibrosis, mucus secretion, cough , Sneezing and dyspnea occur mainly in childhood, whereas chronic obstructive pulmonary disease affects peripheral airways and causes epithelial metaplasia, parenchymal destruction, chronic bronchitis, emphysema ) In that they occur mainly in adulthood; In asthma, mast cells, eosinophils, CD4 + cells, macrophages and the like mainly act on asthma, whereas chronic obstructive pulmonary disease is mainly caused by neutrophils and CD8-cells. Leukotriene B, histamine, IL-4 (interleukin-14), IL-5 (interleukin-5), IL-13 (interleukin (TNF-a), IL-8 (interleukin-8), and GRO (inflammatory cytokines) are involved in the pathogenesis of chronic obstructive pulmonary disease -α (growth related oncogene-α) are mainly involved in the different pathological mechanisms.

As described above, the respiratory inflammatory diseases have some differences in the cause and symptoms of the respiratory diseases, but they have a common point in terms of inflammatory diseases. Among the currently used medicines, the airway dilator simply alleviates symptoms, Drug resistance may occur and there is a fear of worsening of the pathology. In addition, steroid drugs, which are known to be effective for inflammation, are problematic for long-term use due to serious side effects and are difficult to take because they are developed in the form of inhalants rather than oral agents. Therefore, in order to minimize the adverse effects of conventional chemicals, development of effective prevention or treatment of respiratory inflammatory diseases using natural materials is required.

Chamaecyparis obtusa ( Chamaecyparis obtusa ) is an evergreen tree native to Japan. It is called conifers, hinoki, cypress and is a conifer plant that has been planted in the southern part of Korea and successfully established and settled. It is 30 ~ 40m in height and 1 ~ 2m in width. The bark is reddish brown, and small needle-shaped leaves are densely grown on branches. Small flowers bloom on branches in spring, green cones ripen in red in October, and cones are 1cm in diameter and consist of 7 ~ 9 pieces of shield scales. Leaves and wood contain 1% essential oil and are used medicinally. It is known that it has antibacterial effect by eliminating harmful substances in the air such as formaldehyde. Among the essential oil components contained in the cuticle, a substance having a high volatility and a high antimicrobial activity is referred to as a 'phytoncide', and the amount of phytoncide derived from the cotton is superior to that of the other hardwoods.

Phytoncide is a natural antimicrobial substance that the trees excrete in the air to defend themselves from pests and microorganisms. In the case of Korea, most of the pickled wood is less than 50 years old and there is not much phytoncide in the woody part. Phytoncide oil extracted from woody parts and phytoncide oil extracted from leaves are slightly different in properties, and phytoncide extracted from leaves is known to be much fresher and better. Such phytoncide is known to have stimulating peripheral blood vessels and enhances psychological stability, cardiopulmonary function, cardiac strengthening, stress relieving action, strong antibacterial action, deodorizing action, fatigue sedation and immune function increasing effect.

Korean Patent Laid-Open Publication No. 2014-0143644 discloses a composition for external skin for improving atopic dermatitis using supercritical extracting white cotton essential oil. In Korean Patent No. 1467675, Discloses a composition for improving atopic dermatitis which is contained as an active ingredient. However, the composition for preventing or treating respiratory inflammatory disease containing the essential oil of the present invention as an active ingredient has not been disclosed.

SUMMARY OF THE INVENTION The present invention has been made in view of the above-described needs. The present inventors extracted essential oils from cotton seedlings, and treated them with peripheral blood mononuclear cells and respiratory epithelial cells treated with inflammation-inducing agents. As a result, The present invention has been completed.

In order to solve the above problems, the present invention provides a health functional food composition for preventing or ameliorating a respiratory inflammatory disease containing an essential oil of whey protein as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing or treating respiratory inflammatory diseases, which comprises a white essential oil as an active ingredient.

The whitening essential oil of the present invention has a merit that it can be taken for a long period of time because it contains a proven white margin and has little toxicity and side effects. In addition, it can be used as a new material for the treatment of respiratory inflammatory disease on the basis of the suppression of inflammatory reaction of peripheral blood mononuclear cells and respiratory epithelial cells and the demonstration of excellent anti - inflammatory effect in an allergic animal model.

Fig. 1 shows the effect of suppressing the inflammatory reaction in the peripheral blood mononuclear cells of the monoaxyl essential oil. PHA 5, 5 μg / ml of phytohemagglutinin only; LPS 10, treated with only 10 [mu] g / ml lipopolysaccharide; 0.20%, pretreatment of PHA (5 ㎍ / ㎖) or LPS (10 ㎍ / ㎖) and treatment of essential oil with 0.20%; Treated with 0.10% PHA (5 ㎍ / ㎖) or LPS (10 ㎍ / ㎖) and treated with 0.10% of white essential oil; 0.05%, PHA (5 ㎍ / ㎖) or LPS (10 ㎍ / ㎖) pretreatment and treated with 0.05% of white essential oil.
Fig. 2 shows the effect of suppressing the inflammatory reaction in the respiratory epithelial cells of the whitening essential oil. NC does DP or DF no treatment; DP 25, Dermatophagoides pteronyssinus extract 25 ug / ml treatment; DP 50, treatment with 50 ug / ml of DP extract; DF 25, 25 μg / ml of Dermatophagoides farinae extract; DF 50, 50 μg / ml of DF extract; NT, whitening oil refining; 0.02%, whitening oil 0.02% treatment; And 0.03%, and a whitening oil 0.03%.
Fig. 3 shows the expression level of NF-kB protein in the respiratory epithelial cells according to the whitening oil treatment.
4 shows the expression levels of interleukin 4 (IL-4) present in the nasal washings of allergic animal models according to the whitening oil treatment. OVA, ovoalbumin.
FIG. 5 shows the results of the nasal epithelial cell thickness (a), inflammatory cell infiltration degree (b), and PAS positive gut cell number change (c) in the allergic animal model according to the whitening refining treatment.

In order to achieve the object of the present invention, the present invention provides a health functional food composition for preventing or ameliorating respiratory inflammatory diseases, which comprises a white essential oil as an active ingredient.

In the health functional food composition for preventing or ameliorating respiratory inflammatory disease according to the present invention, the above-mentioned whitening essential oil may be one produced by a high-temperature steam extraction method, specifically, Steam is supplied to vaporize the phytoncide, and then the steam containing phytoncide is cooled to be converted into condensed water. The purified oil fraction is separated from the condensed water to extract a high purity whitening essential oil. But is not limited thereto.

Extraction of the above-described whitening essential oil of the present invention can be performed by various methods known in the art, and is not limited to a specific method.

In addition, the present invention relates to a health functional food composition for preventing or ameliorating a respiratory inflammatory disease, wherein the respiratory inflammatory disease is selected from the group consisting of bronchitis, allergic rhinitis, otitis media, sore throat, tonsillitis, pneumonia, asthma and chronic obstructive pulmonary disease COPD), but the present invention is not limited thereto.

The asthma may be selected from the group consisting of bronchial asthma, atopic asthma, non-atopic asthma, allergic asthma and non-allergic asthma, but is not limited thereto.

The bronchitis may be selected from the group consisting of acute bronchitis, chronic bronchitis, bronchiolitis, catarrhal bronchitis and inflammatory bronchitis, but is not limited thereto.

The health functional food is not particularly limited as long as it can be ingested for prevention or improvement of respiratory inflammatory diseases.

Furthermore, since the health functional food composition of the present invention contains the proven linen of safety, there is little toxicity and side effects, so that it can be safely used even for long-term use for the purpose of prevention of respiratory diseases.

When the whitening essential oil of the present invention is used as a food additive, the whitening essential oil may be directly added or used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment).

There is no particular limitation on the kind of the food of the present invention. Examples of products that can be supplemented with the above-mentioned whitening essential oil include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen noodles, gums, ice cream, soups, drinks, tea drinks, Alcoholic beverages, and vitamin complexes, all of which include health functional foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, desaccharides such as maltose and sucrose, and dextrin, cyclodextrin, Polysaccharides such as xylitol, sorbitol, erythritol, and the like.

 Natural flavors such as thaumatin and stevia extract, synthetic flavors such as saccharin, aspartame and the like can be used as the flavor. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the white essential oil of the present invention.

In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, salts of pectic acid, alginic acid and its salts, organic acids, protective colloid sensitizers, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the health functional food composition of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The present invention also provides a pharmaceutical composition for preventing or treating a respiratory inflammatory disease containing an essential oil of wheat flour as an active ingredient.

The pharmaceutical composition of the present invention may be administered to various mammals including rats, mice, livestock, humans, and the like in a variety of routes including, for example, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine or intracerebroventricular ) Injection. ≪ / RTI > Accordingly, the pharmaceutical composition may be formulated into conventional pharmaceutical formulations known in the art. The pharmaceutical composition may be formulated into any formulation including, but not limited to, oral administration formulations, injectable preparations, suppositories, percutaneous administration formulations and expectorant formulations, but is preferably formulated into liquids, suspensions, powders, granules, Such as tablets, capsules, pills, emulsions, syrups, aerosols, or excipients.

When the pharmaceutical composition containing the whitening essential oil of the present invention is formulated into each of the above-mentioned formulations, it may be prepared by adding a pharmaceutically acceptable additive necessary for the preparation of each of the formulations. Typically, the formulation for oral administration may include at least one selected from the group consisting of diluents, lubricants, binders, releasing agents, sensing agents, stabilizers and preservatives as the additives when formulating the composition. Optionally, one or more selected from fragrances, vitamins and antioxidants More than one species can be selected and used.

Examples of the diluent include lactose, dextrose, sucrose, corn starch, soybean oil, microcrystalline cellulose, sorbitol, xylitol or the like. Mannitol, a lubricant such as stearic acid, magnesium or talc, and polyvinylpyrrolidone or hydroxypropylcellulose as a binding agent. Examples of the sealing agent include carboxymethylcellulose calcium, starch glycolic acid ditol, polacrilin potassium or crospovidone, sweeteners such as white sugar, fructose, sorbitol or aspartame, stabilizers such as carboxymethylcellulose sodium, beta-cyclodextrin, As the preservative, methyl paraoxybenzoate, propylparabenzoyl peroxide or potassium sorbate is preferable.

The composition of the present invention can suitably increase or decrease the mixing ratio of the whitening essential oil within the range of effectively maintaining the effect of preventing, ameliorating or treating respiratory-tract inflammatory disease.

The pharmaceutical composition of the present invention can be suitably administered or administered according to the patient's age, sex, weight, diet, excretion rate, severity, other drugs currently being used. Therefore, the pharmaceutical composition should be prepared considering the effective dose range, and the formulated unit dosage form may be prepared according to the judgment of the expert who monitors or observes the administration of the drug as needed, It can be administered several times at time intervals. Accordingly, the dosage is not limited in any way to the scope of the present invention.

Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

Materials and methods

1. Separation of cottonseed oil

After finishing the phytoncide by steam, the steam containing the phytoncide was condensed again and separated from the water to extract the highly pure whitening essential oil. The 12-month stabilizer Of crude oil was used.

2. Isolation of peripheral blood mononuclear cells and induction of inflammatory reaction

Peripheral blood mononuclear cells were separated from normal human blood 20 ml and mononuclear cells at a concentration of 2x10 ⁶ cells / ml were incubated with 10% calf serum, 2 袖 mol / L glutamine and 50 袖 mol / L 2-mercaptoethanol ) Was cultured in RPMI-1640 medium (Roswell Park Memorial Institute medium-1640) at 37 ° C and 5% CO ₂ . At this time, 5 μg / ml of phytohemagglutinin (PHA) and 10 μg / ml of lipopolysaccharide (LPS) were added for 72 hours to induce inflammation. Lt; 0 > C.

3. Induction of Respiratory Infection of Respiratory Epithelial Cells

Respiratory epithelial cells (BEAS-2B) were cultured in DMEM / F12 (Dulbecco Modified Eagle Medium: Nutrient) supplemented with 10% fetal bovine serum, 100 U / ml penicillin, 100 μg / ml streptomycin Mixture F-12 (Ham`s) medium at 37 ° C and 5% CO ₂ . After that, the culture medium was replaced with keratinocyte-serum free medium, and the powder of house dust mite extract (longitudinal dust mite: DP, large legged dust mite: DF, Greer Laboratories, USA) And then cultured for 48 hours to induce inflammation. Only supernatant was taken and stored at -70 ° C for freezing.

4. Analysis of inhibitory effect of leukocyte essential oil on peripheral blood mononuclear inflammation

Interleukin-5 (IL-5), interferon-gamma (INF-gamma), and tumor necrosis (IL-5) in the peripheral blood mononuclear supernatant were measured using an enzyme-linked immunosorbent assay (ELISA) kit Tumor necrosis factor-alpha (TNF-alpha) levels were measured. Each chemoattractant primary antibody and secondary antibody was reacted in order and 3,3 ', 5,5'-tetramethyl benzidine was added to develop color. Absorbance was measured at 450 nm with ELIZA reader. The concentration of the sample was converted from the graph using the medium standard solution.

5. Analysis of inhibitory effect of leukocyte essential oil on respiratory epithelial cell inflammation response

Interleukin-6 (IL-6) and interleukin-8 (IL-8) of the respiratory epithelial cell supernatant were measured using the above ELISA kit. Each of the chemoattractant primary and secondary antibodies was reacted in order and 3,3 ', 5,5'-tetramethylbenzidine was added to develop color. Absorbance was measured at 450 nm with an ELIZA reader. The concentration of the sample was converted from the graph using the graph.

6. Western blotting

For protein extraction, NE-PER nuclear and cytoplasmic extraction reagents (Pierce Chemical, USA) were used. First, DP and DF-treated cells were collected in respiratory epithelial cells using Trypsin-EDTA, centrifuged at 1,200 rpm for 10 minutes, and 100 μl of ice-cold CER I (cytoplasmic extraction reagent I) Lt; / RTI > for 10 minutes. 5.5 μl of ice-cold CER Ⅱ (cytoplasmic extraction reagent Ⅱ) was added and incubated for 1 min. After centrifugation at 4 ° C and 12,000 rpm for 5 min, the supernatant of cytoplasmic extract was collected and stored at -80 ° C. The pellet was washed twice with PBS to remove the remaining cytoplasmic extract. 30 μl ice-cold NER (nuclear extraction reagent) was added to the pellet, reacted at 4 ° C for 40 minutes, and then centrifuged at 12,000 rpm for 10 minutes. The nuclear extracts were stored at -80 ° C. until the experiment and the amount of protein was quantified using BCA protein quantification kit (Pierce Chemical, USA).

The quantified protein samples were electrophoresed in the same amount in NuPAGE 4-12% Bis-Tris gel (Invitrogen, USA) and then transferred to a nitrocellulose membrane (Bio-Rad Inc., USA) using Xcell Surelock Lt; / RTI >

The transferred membrane was washed in the washing solution and reacted in the blocking solution for 1 hour. After the reaction, the primary antibody of NF-kB was added to the diluted 1: 1,000 solution in blocking solution at 4 ° C overnight. The next day, HRP-conjugated goat anti-rabbit IgG secondary antibody was added to the solution diluted 1: 5,000 in the blocking solution and allowed to react at room temperature for about 1 hour. The antibody-reacted membrane was sensitized to X-ray film using SuperSignal West Pico Chemiluminescent Substrate (Pierce Chemical) and developed. The band intensities of the protein were measured using multi Gauge v2.02 (Fujifilm, Japan) Respectively.

7. Statistical Analysis

Statistical analysis was performed using the Kruskal-Wallis ANOVA to test the standard differences between the groups. One-way ANOVA was used for statistical significance. ^* P <0.05 depending on significance level.

Example 1 Inhibitory Effect of Perfumed Essential Oil on Inflammation Response of Peripheral Blood Mononuclear Cells

To investigate the effect of hemicellulase on the inflammatory response of peripheral blood mononuclear cells, monocytes of peripheral blood mononuclear cells pretreated with PHA (5 ㎍ / ㎖) and LPS (10 ㎍ / ㎖) 0.2%), and the inflammation inhibitory effect was measured by an ELISA kit.

As a result, it was confirmed that the production of INF-γ and TNF-α by PHA and LPS was remarkably inhibited in the case of treating the monoaxial essential oil as compared with the untreated untreated control. Particularly, INF -γ and TNF- [alpha] production was significantly reduced (Fig. 1).

Example 2. Analysis of inhibitory effect of respiratory epithelial cells on the inflammatory response by the whitening essential oil

To investigate the effect of the oil on the inflammatory response of respiratory epithelial cells, the mono - secretory oil (0.02% and 0.03%) was administered to the respiratory epithelial cells pretreated with DP and DF (25 and 50 ㎍ / The inflammation inhibitory effect was measured by an ELISA kit.

As a result, it was confirmed that the production of IL-6 and IL-8 by DP and DF was significantly suppressed in the case of the treatment with the whitening oil, compared with the control without the whitening oil treatment, and 0.02% and 0.03% , IL-6 and IL-8 production was significantly decreased (FIG. 2).

Example  3. Whitening oil  Of respiratory epithelial cells NF - kB  Expression level analysis

Activation of NF-κB, a transcription factor of genes involved in the production of inflammatory mediators, is crucial to the inflammatory action of macrophages. Inflammatory genes such as inducible nitric oxide synthase (iNOS2), cyclooxygenase (COX-2), TNF-α, IL-6 and IL- lt; / RTI &gt; In the present invention, Western blotting was carried out to examine the expression of NF-κB when treated with an essential oil (0.03, 0.05%) on inflammatory respiratory epithelial cells.

As a result, it was confirmed that the expression amount of NF-κB protein was significantly reduced in the case of treatment with the whitening essential oil compared with the untreated control (FIG. 3).

Example 4. Inflammation Inhibitory Effect Analysis of Cotton White Essential Oil in Animal Model

Animals were fed free of diets and water in a breeding room of a 6-week-old female BALB / C mouse (Hyochang, Korea) at a temperature of 22 ± 3 ° C, a humidity of 50 ± 10% And adapted for a week.

4-1. Induction of allergic rhinitis in animal models

A mixture of 75 μg of ovoalbumin (OVA) and 2 mg of aluminum hydroxide in 200 μl of a solvent was intraperitoneally administered to BALB / C mice at 0, 7, 14 and 21 days. Thereafter, 500 μg of OVA was injected into the nasal cavity of each side (20 μl) from the 22th to the 30th day for sensitization. To confirm the anti-inflammatory effect of the essential oil, mononuclear essential oil (0.05%, 0.1%, 0.2%) was administered intranasally 22 to 30 days before the OVA treatment and the mice were sacrificed 24 hours after the last OVA administration .

4.2 Measurement of IL-4 expression in nasal washings of animal models

IL-4 was measured by ELISA kit in order to examine the inhibitory effect of allergic rhinitis mice on the nasal inflammation reaction. IL-4 is a representative substance that exhibits allergic inflammatory response, infectious inflammatory response and inflammatory response inhibitory effect.

One hour prior to OVA allergic conjunctivitis, pre-treatment of both nasopharynx with concentrations of 0.05%, 0.1%, 0.2%, and mice were sacrificed 24 hours after the last treatment. At this time, blood was collected from the inferior vena cava and tracheostomy was performed. The level of IL-4 was measured using the obtained nasal washings as a sample.

As a result, it was confirmed that the concentration of IL-4 present in the nasal washings was significantly reduced in the case of treatment with the monoaxial essential oil as compared with the group treated with only OVA (FIG. 4). As a result, it was confirmed that the monofilament essential oil of the present invention had an inflammatory response inhibitory effect in an animal model.

4.3 Histopathological examination

After the sacrifice of the mice, tracheostomy was performed and nasal flushing was performed, and the inflammatory changes of the nasal mucosa were observed under a microscope.

Infiltration of submucosal inflammatory cells was observed at 200-fold and 400-fold magnification after hematoxylin-Eosin (H & E) staining. The number of infiltration of inflammatory cells was 0 points, 2, and 3). The thickness of epithelial cells and the number of mucus-secreting cells were determined by the number of cells stained with Periodic Acid-Schiff (PAS).

As a result, the thickness of mouse nasal epithelial cells was significantly decreased in the 0.2% concentration of the whitening treatment group compared with that of the allergic rhinitis induction group (OVA), and the degree of inflammatory cell infiltration was 0.1 % And 0.2%, respectively (Figs. 5A and 5B).

When the allergic rhinitis caused by OVA is induced, goblet cell metaplasia, which is a mucous secretory cell in the respiratory epithelium, is induced, and mucous secretion is increased due to increased epithelial cell layer damage and goblet cell proliferation . Therefore, the number of positive goblet cells was determined by PAS (Periodic Acid-Schiff) staining. The number of positive goblet cells in the group treated with 0.05%, 0.01% and 0.2% And the number of cells was significantly reduced (FIG. 5C).

From the above results, it was confirmed that the white essential oil of the present invention has an excellent effect on inhibition of the inflammatory reaction of inflammatory diseases, particularly respiratory inflammatory diseases.

Claims (7)

After the phytoncide is vaporized, the water vapor containing phytoncide is cooled and converted into condensed water, and the essential oil fraction is separated from the condensed water and extracted. A health functional food composition for preventing or ameliorating allergic rhinitis comprising an essential ingredient of a white essential oil produced through a stabilizer. delete delete delete delete After the phytoncide is vaporized, the water vapor containing phytoncide is cooled and converted into condensed water, and the essential oil fraction is separated from the condensed water and extracted. A pharmaceutical composition for the prevention or treatment of allergic rhinitis comprising, as an active ingredient, a white essential oil produced through a stabilizer. delete

Images